Laduti vs minoxidil 5%: an evidence-based comparison for androgenetic alopecia

Laduti vs Minoxidil 5%: An Evidence-Based Comparison for Androgenetic Alopecia

When people start noticing more hair on the pillow or a widening parting, they usually face a confusing choice: should they use a well-known medicine like minoxidil 5%, or try a modern cosmetic serum such as Laduti, marketed heavily on social media across Europe? Both promise better hair, but they belong to two very different worlds, pharmaceutical medicine on one side, cosmetic care on the other. This article offers a rigorous, easy-to-understand comparison based on peer-reviewed clinical trials, European regulations, and the latest 2024 to 2026 evidence.

Understanding Androgenetic Alopecia

Androgenetic alopecia (AGA), also called male-pattern or female-pattern hair loss, is the most common cause of hair thinning worldwide. It affects roughly 80% of Caucasian men and up to 40% of women during their lifetime. The mechanism is essentially hormonal and genetic. In genetically predisposed people, the enzyme 5-alpha-reductase (a biological catalyst that speeds up chemical reactions in the body) converts testosterone into dihydrotestosterone (DHT), a powerful hormone derived from testosterone that shrinks scalp follicles over time. This process, called follicular miniaturization (where hair follicles gradually shrink and weaken), gradually replaces thick terminal hairs with thin, peach-fuzz-like vellus hairs.

What Is Minoxidil 5%?

Origin and mechanism

Minoxidil was originally developed as an oral antihypertensive (a medication to lower high blood pressure) in the 1970s. Its topical formulation (applied directly to the scalp) was approved in 1988 for AGA. It is a prodrug, meaning it is an inactive substance that must be converted by the body into an active form, activated by scalp sulfotransferase (SULT1A1) (a specific enzyme found in hair follicles) into minoxidil sulfate. Once active, it opens ATP-sensitive potassium channels (microscopic pathways that regulate cell activity), dilates perifollicular blood vessels to increase blood flow, releases VEGF (vascular endothelial growth factor, a protein that stimulates new blood vessel growth), prolongs the anagen phase (the active growth stage of the hair cycle), and protects dermal papilla cells (the cells at the base of the hair follicle responsible for hair growth) from apoptosis, which is programmed cell death. Notably, minoxidil does not block DHT, which means its effect is androgen-independent (acting without affecting male sex hormones).

Clinical evidence

• Olsen et al. 2002 (study of n=393 men over 48 weeks): 5% strength was significantly superior to the 2% version and a placebo (an inactive dummy treatment), showing 45% more hair regrowth than the 2% formulation.

• Tsuboi et al. 2009 (study of n=300 men over 24 weeks): the 5% concentration added 26.4 thick, non-vellus hairs per square centimetre compared to 21.2 hairs for the 1% concentration (a statistically significant difference with a p-value of 0.020).

• Olsen et al. 2007 (study of n=352 men): the 5% topical foam formulation significantly increased hair counts compared to a placebo (with a highly significant clinical p-value of less than 0.0001).

• Lucky et al. 2004 (study of n=381 women over 48 weeks): the 5% formulation proved highly superior to a placebo across all measured goals and endpoints in female-pattern hair loss.

A 2022 network meta-analysis (a large-scale study combining and comparing data from multiple previous trials) confirmed an average gain of about +21 hairs/cm² versus only +5 to +9 hairs/cm² for a placebo after 16 to 48 weeks. This represents a real, clinically proven, though modest effect.

Regulatory status in Europe

Topical minoxidil is classified as an official medicinal product (a drug) in the European Union, making it available over-the-counter in pharmacies. Because of its solid scientific backing, it is graded with a high Evidence Level 1 to 2 in the European Dermatology Forum (EDF) S3 clinical guideline for the treatment of androgenetic alopecia.

Side effects

Local side effects of minoxidil include itching, redness, skin dryness, flaking, an initial temporary phase of hair shedding, and hypertrichosis (the growth of unwanted facial or body hair). Rare systemic effects (reactions affecting the whole body rather than just the skin) include palpitations or oedema (fluid retention causing swelling). A Saudi cohort (a tracked group of patients) of 400 individuals reported an 86.3% discontinuation rate within a few years, primarily due to these side effects and slow, gradual results.

What Is Laduti?

Laduti is a topical hair serum marketed by Lazru Cosmetics Trading L.L.C., mainly through direct-to-consumer online channels in Europe. It is not classified as a medicine, indeed, it falls under EU Regulation (EC) No 1223/2009, which governs cosmetic products. Its formula combines two active patent complexes, Procapil and AnaGain, suspended in a liposomal base (a delivery system using microscopic fat bubbles called liposomes to help active ingredients penetrate deeper into the skin).

Procapil

Developed by Sederma in France, Procapil combines three key ingredients: biotinyl-GHK (a small protein molecule or tripeptide designed to strengthen hair anchoring in the scalp), apigenin (a plant-derived citrus flavonoid known for promoting localized microcirculation or blood flow), and oleanolic acid (a natural compound extracted from olive leaves that acts as a 5-alpha-reductase inhibitor to block DHT). Because most published clinical trials combine Procapil with other active ingredients, its isolated, individual effect remains unknown. A 2025 review classified its clinical evidence as Level 2, derived solely from studies of combination products.

AnaGain

This is a patented organic pea sprout (Pisum sativum) extract developed by Mibelle Biochemistry in Switzerland. Its main mechanism of action is the stimulation of FGF7 (fibroblast growth factor 7, a protein that signals cells to grow) and Noggin (a signaling protein that helps initiate new hair growth) directly within dermal papilla cells. Grothe et al. (2019) reported that a 2% AnaGain lotion increased FGF7 gene expression by 56% and Noggin by 85% in a small group of 10 volunteers. Another study with a sample size of n=20 over 3 months improved the anagen-to-telogen ratio (the proportion of growing hair to resting hair) from 4.0 to 7.2, representing a 78% increase. However, these are very small, supplier-funded studies without any independent, placebo-controlled RCT (randomized controlled trial, the gold standard of scientific research).

Liposomal delivery

Tiny lipid vesicles (microscopic fat bubbles smaller than 200 nanometres) enhance the penetration of ingredients and create a slow-release reservoir in the scalp. Better penetration, however, does not automatically translate into superior clinical results for hair regrowth.

Head-to-Head Comparison

Two Different Philosophies

The comparison is, at its core, between two distinct categories of products. Minoxidil works downstream, meaning it directly stimulates the biological pathways that push follicles back into the active growth phase regardless of underlying hormones. On the other hand, Laduti works upstream, attempting to tackle the root causes by reducing local DHT, stimulating FGF7 and Noggin growth factors, improving scalp microcirculation, and reinforcing hair anchoring. While this approach is elegant on paper, in clinical practice, no large-scale trial has proven meaningful hair regrowth. It is also worth noting that minoxidil requires the scalp enzyme SULT1A1 to work, as 30% to 50% of patients are low responders who lack sufficient levels of this enzyme, which is exactly why cosmetic adjuncts (supporting treatments) attract so much interest.

European Regulatory Landscape

Under the strict European Regulation (EC) No 1223/2009, a cosmetic product cannot legally claim to treat, cure, or prevent any human disease. Furthermore, Regulation (EU) No 655/2013 requires all cosmetic claims to be completely truthful and backed by solid scientific evidence. As a result, Laduti can state that it "reduces the appearance of hair loss", but it is legally forbidden from claiming to "treat androgenetic alopecia". Minoxidil, being an approved medicine, is permitted to make clear therapeutic claims after passing rigorous regulatory safety and efficacy assessments. This legal gap reflects a fundamental difference in the depth of clinical evidence available.

Clinical Decision Framework

Confirmed AGA, moderate to advanced

For individuals with a confirmed diagnosis of androgenetic alopecia, topical minoxidil 5% (or off-label low-dose oral minoxidil, meaning a drug prescribed for a purpose other than its official approval, used under medical supervision) remains the first-line treatment according to the European Dermatology Forum S3 guidelines and the 2024 AEDV Spanish consensus. In men, combining minoxidil with prescription medications like finasteride 1 mg or dutasteride 0.5 mg (which directly block DHT production) yields significantly greater efficacy. A cosmetic serum cannot substitute for this medical standard of care.

Very early thinning or patients refusing pharmaceuticals

Laduti may be an acceptable option if personal expectations remain realistic and the patient fully understands that no independent, placebo-controlled RCT (randomized controlled trial) has yet proven its clinical efficacy in treating androgenetic alopecia.

Minoxidil non-responders or intolerant

For those who do not respond to minoxidil or cannot tolerate it, alternative options include low-dose oral minoxidil, a prescription 5-alpha-reductase inhibitor (a drug that stops testosterone from turning into DHT), scalp microneedling (using tiny needles to stimulate growth factors), or an adjunctive cosmetic serum. In this context, Laduti could fit as a helpful daily complement, but not as a replacement for standard medical treatments.

Women of childbearing age

For women of childbearing age, topical minoxidil 2% is the standard first-line treatment recommended by the European Dermatology Forum, with the 5% strength used cautiously. Oral treatments like finasteride and dutasteride are strictly contraindicated in pregnancy, meaning they must never be used due to severe risks to an unborn child. A cosmetic serum like Laduti offers no known teratogenic risk (the risk of causing birth defects), but this safety benefit is not equivalent to proven biological efficacy.

Can You Combine Laduti and Minoxidil?

There is no known pharmacological incompatibility (harmful interaction between the chemical substances) when using these products together. Some hair specialists recommend applying minoxidil first, letting it dry completely, and then applying a cosmetic serum. However, robust combination RCTs (high-quality clinical studies) are still lacking, so you should discuss this approach with a dermatologist to avoid excessive scalp irritation.

Adherence: The Silent Determinant

Even the most advanced hair loss treatment fails if it is not used consistently. Real-world data show that 86% to 95% of patients stop using topical minoxidil within one year, mainly due to the daily commitment required, skin irritation, and the slow visibility of visible results, which take a minimum of 6 to 12 months to appear. Cosmetic serums often offer a more pleasant scalp experience, which can potentially improve user adherence (how consistently a patient sticks to their treatment plan), but this psychological advantage should not be confused with proven biological efficacy.

Conclusion

The comparison is, at its core, between two distinct categories of hair care products. Minoxidil 5% is an approved European medicinal product backed by decades of rigorous RCTs, international guidelines, and ongoing pharmacovigilance (the systematic monitoring of a drug's safety after it is approved). Laduti, conversely, is a well-formulated cosmetic serum whose active ingredients have a plausible biological rationale but lack any independent, placebo-controlled RCT proving actual hair regrowth in androgenetic alopecia. For confirmed AGA, minoxidil remains the evidence-based first choice, ideally combined with a prescription 5-alpha-reductase inhibitor (a DHT-blocking medicine) in men. Cosmetic serums may play a useful complementary role but cannot substitute for a proven medical treatment. In addition, tools such as Hairdex, a clinically validated quality-of-life instrument (a standardized questionnaire designed to measure patient satisfaction), can help patients and clinicians measure not only physical follicle density but also overall personal wellbeing.

FAQ

Is Laduti as effective as minoxidil 5%?

No independent, placebo-controlled RCT (randomized controlled trial) has demonstrated that Laduti has results comparable to minoxidil. Minoxidil has decades of solid scientific evidence showing an average increase of about +21 hairs/cm² compared to a placebo.

Is Laduti approved by the EMA?

No. Laduti is classified as a cosmetic product under EU Regulation 1223/2009 and therefore does not require official authorisation from the EMA (European Medicines Agency), which only regulates medicinal drugs.

Can I use Laduti instead of minoxidil to avoid side effects?

You can, but you would be giving up the strongest, most scientifically proven treatment option available. Alternatives to the traditional minoxidil liquid solution include minoxidil foam, which is formulated without propylene glycol (a common solvent that often causes scalp irritation), or low-dose oral minoxidil under close medical supervision.

How long before I see results?

Minoxidil generally requires 3 to 6 months of daily application before showing a visible effect, with the maximum hair regrowth benefit peaking at around 12 months. Cosmetic hair serums are typically marketed with similar timelines, though they lack the same level of objective, independent scientific evidence.

Can Laduti and minoxidil be used together?

No major pharmacological incompatibility is known between the two products. You should apply minoxidil first, let it dry completely on the scalp, and then apply the cosmetic serum. Always consult a dermatologist before combining treatments.

References

[1] Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002. Read the source

[2] Braschi É, Kiciak A, Young J. Topical minoxidil for androgenetic alopecia: When blood pressure agents make you hairy. Can Fam Physician. 2025. Read the source

[3] Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004. Read the source

[4] Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007. Read the source

[5] Tsuboi R, Arano O, Nishikawa T, et al. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men. J Dermatol. 2009. Read the source

[6] Patel P, Nessel TA, Kumar D D. Minoxidil. StatPearls. 2023. Read the source

[7] Choi N, Shin S, Song SU, Sung JH. Minoxidil Promotes Hair Growth through Stimulation of Growth Factor Release from Adipose-Derived Stem Cells. Int J Mol Sci. 2018. Read the source

[8] Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004. Read the source

[9] Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. European Dermatology Forum. Read the source

[10] Ho CH, Sood T, Zito PM. Androgenetic Alopecia. StatPearls. 2024. Read the source

[11] Bikash C. Topical Alternatives for Hair Loss: Beyond the Conventional. Int J Trichology. 2025. Read the source

[12] Grothe T, Wandrey F, Schuerch C. Short communication: Clinical evaluation of pea sprout extract in the treatment of hair loss. Phytother Res. 2019. Read the source

[13] TR et al. A Comparative Study of Topical Procapil With Platelet-Rich Plasma Therapy Versus Topical Redensyl, Saw Palmetto, and Biotin With Platelet-Rich Plasma Therapy in the Treatment of Androgenetic Alopecia. Cureus. 2023. Read the source

[14] European Parliament and Council. Regulation (EC) No 1223/2009 on cosmetic products. Official Journal of the European Union. 2009. Read the source

[15] European Commission. Commission Regulation (EU) No 655/2013 laying down common criteria for the justification of claims used in relation to cosmetic products. Official Journal of the European Union. 2013. Read the source

[16] European Parliament and Council. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. Official Journal of the European Union. 2009. Read the source

[17] Shadi Z. Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia. Dermatol Ther (Heidelb). 2023. Read the source

[18] Sharma A, Mohapatra H, Arora K, et al. Bioactive Compound-Loaded Nanocarriers for Hair Growth Promotion: Current Status and Future Perspectives. Plants (Basel). 2023. Read the source